Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

This summary is generated by an algorithm. If you find any mistakes, let us know.

ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
UN

Unicorn Nest news

ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

Source
Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes
Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes
UN

Unicorn Nest news

Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes

– Hexagon Bio, a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome, announced that it has raised $61 million to fuel the continued development of its platform to design and develop new therapeutics mined from microbial genomes.
Nextech Invest led the financing, with participation from new investors SoftBank Vision Fund 2* and Casdin Capital, as well as existing investors The Column Group, 8VC, and Two Sigma Ventures.
– Hexagon’s interdisciplinary platform combines technological advances and proprietary insights across machine learning, genomics, synthetic biology and automation to systematically discover new chemical compounds linked to known protein targets.
– Hexagon has built a database of microbial genomes that is more than twice the size of all public databases and is adding thousands of additional genomes per month.

Source
ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform
ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform
UN

Unicorn Nest news

ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform

– ROME Therapeutics announced the completion of a $77m Series B financing round.
– The round was led by new investor Section 32 and included participation from Sanofi Ventures, Casdin Capital, Andreessen Horowitz and Alexandria Venture Investments.
– ROME’s mission is to harness the power of the repeatome – the roughly 60% of the human genome consisting of repetitive sequences of nucleic acids, known as repeats – to discover powerful new classes of medicines for cancer and autoimmune diseases.
– ROME has identified multiple repeatome-derived targets and created an internal data science platform, called repeatomics, to analyze vast quantities of data available through the repeatome.

Source
SeQure Dx Announces $17.5M Series A Funding
SeQure Dx Announces $17.5M Series A Funding
UN

Unicorn Nest news

SeQure Dx Announces $17.5M Series A Funding

– SeQure Dx is a gene-editing diagnostics company.
– It announced a $17.5m Series A funding.
– The funding was led by RiverVest Venture Partners and Mass General Brigham Ventures along with Digitalis Ventures, Casdin Capital, KdT Ventures, Bold Capital Partners and Alexandria Venture Investments.
– Funds will be used for initial company development leading to establishment of a full-service laboratory providing off-target gene-editing analysis for use in drug development, clinical trials and ultimately patient evaluation prior to therapy.
– SeQure Dx was founded on exclusive licensure of GUIDE-seq, ONE-seq and related assay technologies for detection of off-target gene-editing events.

Source
Zentera Therapeutics Raises $75M in Series b Funding
Zentera Therapeutics Raises $75M in Series b Funding
UN

Unicorn Nest news

Zentera Therapeutics Raises $75M in Series b Funding

– Zentera Therapeutics, a Shanghai, China-based clinical-stage biopharmaceutical company, raised $75M in Series B funding.
– The round was led by OrbiMed Advisors Asia and Tybourne Capital Management with participation from Avidity Partners, Casdin Capital, Surveyor Capital, Farallon Capital Management, Lilly Asia Ventures, Logos Capital, Perceptive Advisors, Redmile Group and Viking Global Investors.
– The company intends to use the funds to advance the development of three Zentalis-discovered oncology clinical candidates as well as business development for future pipeline additions in China.

Source
T-knife Therapeutics Closes $110M Series B Financing
T-knife Therapeutics Closes $110M Series B Financing
UN

Unicorn Nest news

T-knife Therapeutics Closes $110M Series B Financing

– T-knife Therapeutics, Inc. from Berlin, Germany develops T-cell receptor (TCR) therapeutics for solid tumor patients.
– Company completed a $110m Series B financing.
– The round was led by Fidelity Management & Research Company, LLC., with participation from other new investors including LSP, Qatar Investment Authority (QIA), Casdin Capital, Sixty Degree Capital, and CaaS Capital, along with existing investors RA Capital Management, Versant Ventures and founding investor Andera Partners.
– The new investment will be used to expand the company’s scientific team, increase manufacturing capacity and advance its pipeline of TCR-T.

Source
TMRW Life Sciences Raises $105M in Funding
TMRW Life Sciences Raises $105M in Funding
UN

Unicorn Nest news

TMRW Life Sciences Raises $105M in Funding

– TMRW Life Sciences, Inc., a NYC-based life sciences technology company providing an automated platform for tracking, monitoring, and storage of frozen eggs and embryos used in in vitro fertilization (IVF), completed a $105m Series C equity and debt financing.
– The equity round was led by Transformation Capital with participation from GV (formerly Google Ventures), Casdin Capital, Peter Thiel, Anne and Susan Wojcicki, and existing investors 5AM Ventures and Life Sciences Innovation Fund, among others.
– The company intends to use the funds to accelerate global expansion, advance product innovation, develop consumer awareness of the platform, and support future business development opportunities.

Source
Prime Medicine Raises $315M in Funding
Prime Medicine Raises $315M in Funding
UN

Unicorn Nest news

Prime Medicine Raises $315M in Funding

– Prime Medicine is a Cambridge MA-based biotechnology company developing gene editing technology.
– The company raised $115M in Series A funding and $200M in Series B funding.
– The Series A round was led by ARCH Venture Partners with participation from F-Prime Capital, GV, and Newpath Partners.
– The Series B included all Series A investors, plus Casdin Capital with participation from Cormorant Asset Management, Moore Strategic Ventures, Public Sector Pension Investment Board, Redmile Group and Samsara BioCapital.

Source
Apton Biosystems Raises $24M in Series A Financing
Apton Biosystems Raises $24M in Series A Financing
UN

Unicorn Nest news

Apton Biosystems Raises $24M in Series A Financing

– Apton Biosystems, Inc. from Pleasanton, CA develops Super-Res sequencing and single-molecule detection systems for large-scale clinical applications such as early cancer detection and population sequencing.
– The company closed a $24m Series A financing.
– The round was led by Kern Capital with participation by new and existing investors including Casdin Capital and Khosla Ventures.
– The company intends to use the funds to continue developing its Super-Res sequencing and single-molecule proteomics detection systems.

Source
Immunotherapy startup Umoja lands $210M, less than a year after raising $53M
Immunotherapy startup Umoja lands $210M, less than a year after raising $53M
UN

Unicorn Nest news

Immunotherapy startup Umoja lands $210M, less than a year after raising $53M

– Umoja Biopharma, a Seattle-based immunotherapy company, raised $210m in Series B funding.
– The round was led by SoftBank Vision Fund 2 and Cormorant Asset Management.
– New investors included RTW Investments, LP, Temasek, Presight Capital, Caas Capital and SVB Leerink.
– Funds also came from existing investors: MPM Capital, DCVC Bio, Qiming Venture Partners USA, Casdin Capital, The Emerson Collective and Alexandria Venture Investments.

Source
Mnemo Therapeutics Announces €75 million Series A to Accelerate Next Generation Integrated CAR-T and Epigenetic Targeting Platform
Mnemo Therapeutics Announces €75 million Series A to Accelerate Next Generation Integrated CAR-T and Epigenetic Targeting Platform
UN

Unicorn Nest news

Mnemo Therapeutics Announces €75 million Series A to Accelerate Next Generation Integrated CAR-T and Epigenetic Targeting Platform

– Mnemo Therapeutics completed its €75m Series A financing.
– The round was led by Casdin Capital, returning investor Sofinnova Partners, and an undisclosed investor, including participation from Redmile, Emerson Collective and Alexandria Venture Investments.
– The Series A financing will allow the company to accelerate development of the EnfiniT targeting and next generation chimeric antigen receptors (CAR) T cell therapy platform combining the pioneering research from Institut Curie and Memorial Sloan Kettering Cancer Center (MSK).

Source
LetsGetChecked Announces $150 Million Series D Fundraise to Grow Comprehensive Virtual Care Capabilities
LetsGetChecked Announces $150 Million Series D Fundraise to Grow Comprehensive Virtual Care Capabilities
UN

Unicorn Nest news

LetsGetChecked Announces $150 Million Series D Fundraise to Grow Comprehensive Virtual Care Capabilities

– LetsGetChecked announced the completion of a $150m Series D round of financing.
– The funding was led by Casdin Capital with continued participation from CommonFund Capital, Illumina Ventures, Optum Ventures, Transformation Capital, HLM Venture Partners, Qiming Venture Partners USA, and professional golfer Rory Mcllroy through Symphony Ventures, an investment partnership.
– This latest financing brings the total capital raised by LetsGetChecked to more than $260m.
– LetsGetChecked will use the new capital to launch care pathways, a 360-degree customer care journey that will provide remote care for patients with ailments and chronic conditions.
– Care pathways is enabled by LetsGetChecked’s core offerings, including telehealth services, pharmacy capabilities, and at-home diagnostics.

Source
NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets
NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets
UN

Unicorn Nest news

NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets

– NiKang Therapeutics Inc. announced the completion of an oversubscribed $200m series C financing led by Cormorant Asset Management, HBM Healthcare Investments and Octagon Capital Advisors with participations from a premier syndicate of funds including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Group, Pavilion Capital, funds and accounts managed by BlackRock, RA Capital Management, Surveyor Capital (a Citadel company), Samsara BioCapital, PFM Health Sciences, Invus, Janus Henderson Investors and Logos Capital.
– All existing investors including CBC Group, RTW Investments, LP, Lilly Asia Ventures, Matrix Partners China, and Casdin Capital participated in the financing.

Source
Flare Therapeutics Raises $82M in Series A Financing
Flare Therapeutics Raises $82M in Series A Financing
UN

Unicorn Nest news

Flare Therapeutics Raises $82M in Series A Financing

– Flare Therapeutics is a biotechnology company based in Cambridge, Mass.
– The company raised $82m in Series A financing.
– The round was led by Third Rock Ventures with participation from Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors and Eventide Asset Management.
– The new investment will be used for further advancement of the company’s lead program in precision oncology toward the clinic.

Source
Exscientia Raises Up To $525M in Funding
Exscientia Raises Up To $525M in Funding
UN

Unicorn Nest news

Exscientia Raises Up To $525M in Funding

– Exscientia is an Oxford, England, UK-based clinical stage pharmatech company using AI to design patient-based drugs.
SoftBank Vision Fund 2 led the Series D funding round and was joined by previous round lead investors – Novo Holdings and funds managed by Blackrock.
– Other investors included Mubadala Investment Company, Farallon Capital, Casdin Capital, GT Healthcare Capital, Marshall Wace, Pivotal bioVenture Partners, Laurion Capital, Hongkou and Bristol-Myers Squibb.
– In addition to the Series D funding round, SoftBank is providing an additional $300m equity commitment that can be drawn at the company’s discretion.

Source
C2i, a genomics SaaS product to detect traces of cancer, raises $100M Series B
C2i, a genomics SaaS product to detect traces of cancer, raises $100M Series B
UN

Unicorn Nest news

C2i, a genomics SaaS product to detect traces of cancer, raises $100M Series B

– C2i Genomics, a cancer detection company, raised $100m in Series B funding.
– The round was led by Casdin Capital and joined by new investors including New Enterprise Associates (NEA), and existing investors including Sequoia Capital, and others.
– The company plans to use the funding to expand its research and development efforts.

Source
Multiply Labs Raises $20M in Series A Funding
Multiply Labs Raises $20M in Series A Funding
UN

Unicorn Nest news

Multiply Labs Raises $20M in Series A Funding

– Multiply Labs, a San Francisco, CA-based robotics company developing automated manufacturing systems for the production of individualized drugs, raised $20m in Series A funding.
– The round was led by Casdin Capital with participation from new investors Lux Capital and Pathfinder, Founders Fund’s early stage investment vehicle, Fifty Years and Garage Capital.
– In conjunction with the funding, Michael Doherty, a representative of Casdin Capital, will join Multiply Labs’ Board of Directors.
– The company intends to use the funds to grow its installed robotic production capacity, and to apply its tech to new life-saving therapies.

C2i Genomics Raises $100M in Funding
C2i Genomics Raises $100M in Funding
UN

Unicorn Nest news

C2i Genomics Raises $100M in Funding

– C2i Genomics from New York, NY provides a cloud-based cancer diagnostics service that uses AI pattern recognition and whole-genome analysis to provide rapid and accurate detection of residual disease.
– The company raised $100m in financing.
– The round was led by Casdin Capital with participation from NFX, Duquesne Family Office, Section 32, iGlobe Partners, Driehaus Capital and others.
– The new investment will be used to accelerate the company’s clinical development and commercialization of its C2-Intelligence Platform.

Leyden Labs Secures €40M in Series A Funding
Leyden Labs Secures €40M in Series A Funding
UN

Unicorn Nest news

Leyden Labs Secures €40M in Series A Funding

– Leyden Labs B.V. from Amsterdam develops a platform that targets commonalities of viral families to protect humanity from known and future viruses.
– Series A €40M round was led by GV (formerly Google Ventures), with participation from F-Prime Capital, Casdin Capital, LLC and Brook Byers.
– The company intends to use the funds to further develop the platform and portfolio of product candidates and to build out the team.

Source
Komodo Health Secures $220M in Funding Led by Tiger Global
Komodo Health Secures $220M in Funding Led by Tiger Global
UN

Unicorn Nest news

Komodo Health Secures $220M in Funding Led by Tiger Global

– Komodo Health announced a $220m Series E funding round.
– The round was led by Tiger Global Management and joined by Casdin Capital.
– Existing investors ICONIQ Growth, Andreessen Horowitz, and SVB Capital also joined the round.
– The investment underscores Komodo Health’s rapidly growing role as a foundational enterprise technology platform helping to drive digital transformation across the healthcare industry.
– The additional funding will allow Komodo Health to accelerate investment in its enterprise technology platform, application suite, and core data assets.
– Together, this combination of robust clinical insights and the ability to infuse them into enterprise workflows is helping the world’s leading life sciences companies, health plans, and patient advocacy groups close gaps in care, address unmet patient needs, improve engagement, and ultimately help drive novel therapies into the market.

Source
Insitro Raises $400M in Series C
Insitro Raises $400M in Series C
UN

Unicorn Nest news

Insitro Raises $400M in Series C

– Insitro, a machine learning-driven drug discovery and development company, has raised $400m in a Series C financing.
– The financing was led by Canada Pension Plan Investment Board (CPP Investments), with significant participation from current investors Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., Casdin Capital, and funds and accounts managed by BlackRock as well as ARCH Venture Partners, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures, HOF Capital and Alexandria Venture Investments.

Source
Paige Secures Financing from KKR for Total Series C Funding Round of Over $125 Million
Paige Secures Financing from KKR for Total Series C Funding Round of Over $125 Million
UN

Unicorn Nest news

Paige Secures Financing from KKR for Total Series C Funding Round of Over $125 Million

– Paige, a global leader in AI-based diagnostic software in pathology, today announced that KKR, a leading global investment firm, joined Casdin Capital and Johnson & Johnson Innovation – JJDC, Inc. (JJDC) as co-leads in its Series C financing round, bringing the round to over $125 million.
– Paige will use this new capital to expand its geographic footprint as it accelerates the development of AI-based clinical applications, biomarkers and diagnostics.
– Additional investors in the Series C round include Catalio Capital Management, existing investors and other funds, as previously announced.
– For KKR, the investment is being funded through the firm’s Health Care Strategic Growth Fund, which is focused on investing in high-growth health care-related companies for which KKR can be a unique partner in helping reach scale.

Source
Amunix Raises $117M in Series B Financing
Amunix Raises $117M in Series B Financing
UN

Unicorn Nest news

Amunix Raises $117M in Series B Financing

– Amunix Pharmaceuticals from South San Francisco develops masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers.
– Series B $117m round was led by Viking Global Investors with participation from a premier syndicate of funds, including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, certain funds managed by Clough Capital Partners, and CaaS Capital Management and existing investors Redmile Group, Venrock, Casdin Capital, Omega Funds, Frazier Healthcare Partners, Longitude Capital, and Polaris Partners.

Source
Century Therapeutics Closes $160M Series C Financing
Century Therapeutics Closes $160M Series C Financing
UN

Unicorn Nest news

Century Therapeutics Closes $160M Series C Financing

– Century Therapeutics, a Philadelphia, PA-based cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, closed a $160m Series C financing.
– The round was led by Casdin Capital and brought together a syndicate of new investors including Fidelity Management & Research LLC, the Federated Hermes Kauffmann Funds, RA Capital, Logos Capital, OrbiMed, Marshall Wace, Qatar Investment Authority, Avidity Partners, and Octagon Capital.
– Eli Casdin, Founder and Chief Investment Officer of Casdin Capital will be joining the Century Therapeutics Board of Directors.

Source
FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
UN

Unicorn Nest news

FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform

– FogPharma announced the completion of a $107m Series C financing round.
– The round was led by venBio Partners with participation from new investors Cormorant Asset Management, Farallon Capital Management, Invus, funds and accounts advised by T. Rowe Price Associates, Inc.; HBM Healthcare Investments, Casdin Capital, and PagsGroup.
– Existing investors, including GV, 6 Dimensions Capital, Deerfield Management and Blue Pool Capital also participated in the oversubscribed round.
– FogPharma’s proprietary hyperstabilized α-helical peptides (Helicon™ peptides) are a new class of therapeutics that combine the targeting strength and specificity of antibodies with the broad tissue distribution, intracellular target engagement and oral dosing optionality of small molecules.

Source
Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline of Precision Oncology and Immunology Programs
Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline of Precision Oncology and Immunology Programs
UN

Unicorn Nest news

Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline of Precision Oncology and Immunology Programs

– Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, announced the completion of a $135 million Series C financing.
– The round was co-led by new investors, Logos Capital and Boxer Capital of Tavistock Group.
– Additional new investors in the raise include SoftBank Investment Advisers, Avoro Capital Advisors, funds and accounts managed by BlackRock, RA Capital Management, funds and accounts advised by T. Rowe Price Associates, Inc., Surveyor Capital (a Citadel company), Woodline Partners LP, Acuta Capital and Driehaus Capital Management, alongside existing investors ARCH Venture Partners, BVF Partners L.P., Casdin Capital, Mubadala Capital, Nextech Invest and Versant Ventures.

Source
Notch Therapeutics Closes $85M Series A Financing
Notch Therapeutics Closes $85M Series A Financing
UN

Unicorn Nest news

Notch Therapeutics Closes $85M Series A Financing

– Notch Therapeutics is a Vancouver, BC-based biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer.
– Company closed an U.S. $85m Series A financing.
– The round was led by an exclusively healthcare-focused investment fund with participation from existing investors Allogene Therapeutics, Inc., Lumira Ventures, and CCRM Enterprises Holdings Ltd., an affiliate of Centre for Commercialization of Regenerative Medicine (CCRM); along with new investors EcoR1 Capital, Casdin Capital, Samsara BioCapital, and Amplitude Ventures.

Source
Pipeline Therapeutics Completes $80 Million Series C Financing
Pipeline Therapeutics Completes $80 Million Series C Financing
UN

Unicorn Nest news

Pipeline Therapeutics Completes $80 Million Series C Financing

– Pipeline Therapeutics completed an $80m Series C financing round.
– The round was led by a healthcare-focused new investor, with participation by other new investors including Perceptive Advisors, Franklin Templeton, Casdin Capital, Samsara BioCapital, Suvretta Capital, Red Tree Venture Capital, and an undisclosed leading global investment fund.
– All of the company’s existing shareholders, including founding investor Versant Ventures, Sectoral Asset Management and Cleva Pharma (a Brace Pharma affiliate), participated in the round.
– Pipeline Therapeutics plans to use the proceeds to advance its development candidates PIPE-505, in patients with sensorineural hearing loss, and PIPE-307, in patients with multiple sclerosis. Proceeds will also be used to advance additional therapeutic candidates and for general corporate purposes.

Source
1 2 3 58 59 60
Crunchbase icon

Content report

The following text will be sent to our editors: